Patients with Alzheimer’s disease (AD) and clinically overlapping neurodegenerative diseases are classified molecularly using the A/T/N classification system. Apart from fluid biomarkers and structural MRI, A/T/N assessment incorporates β-amyloid-PET (A), tau-PET (T), and [18F]FDG-PET (N). We evaluated if dynamic featu...
Johannes S. Gnörich, J. Kusche-Palenga, Agnes Kling et al.· Molecular Neurodegeneration· 0 citations
While nigrostriatal dopaminergic cell loss is the pathological hallmark of Parkinson's disease, it is well-known that dopamine deficiency cannot fully explain the clinical severity or disease progression. Emerging data suggest that resilience, i.e. the brain's capacity to maintain function despite pathology, plays a ke...
M. C. Ruppert-Junck, T. van Eimeren, Kathrin Giehl et al.· Brain : a journal of neurolo...· 0 citations
Dopaminergic depletion is associated with a targeted SMN reorganization, potentially maintaining network information flow despite progressive hub loss, and whether this reorganization represents compensation or a consequence of progressive pathology requires further longitudinal assessment.
Adrian L. Asendorf, Verena Dzialas, T. van Eimeren et al.· Movement Disorders· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.